News stories about ACADIA Pharmaceuticals (NASDAQ:ACAD) have trended somewhat positive on Saturday, according to AlphaOne Sentiment Analysis. The research firm, a subsidiary of Accern, identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. ACADIA Pharmaceuticals earned a coverage optimism score of 0.04 on AlphaOne’s scale. AlphaOne also gave press coverage about the biopharmaceutical company an impact score of 69 out of 100, indicating that recent media coverage is likely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have impacted Alpha One Sentiment Analysis’s scoring:
- Time to Reconsider Lexicon Pharmaceuticals Incorporated (NASDAQ:LXRX) After More Short Sellers? (upbeacon.net)
- ETFs with exposure to ACADIA Pharmaceuticals, Inc. : June 16, 2017 (finance.yahoo.com)
- ACADIA Pharmaceuticals Inc. (ACAD) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
- Overview Of Different Chart Patterns: ACADIA Pharmaceuticals Inc. (ACAD), Inphi Corporation (IPHI) – AllStockNews (allstocknews.com)
- ACADIA Pharmaceuticals Inc. (ACAD) Receives $41.09 Consensus PT from Analysts (fumbleboard.com)
Shares of ACADIA Pharmaceuticals (NASDAQ ACAD) opened at 27.10 on Friday. The stock has a 50 day moving average of $28.46 and a 200-day moving average of $31.94. The firm’s market capitalization is $3.31 billion. ACADIA Pharmaceuticals has a 52-week low of $20.68 and a 52-week high of $40.83.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.72) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.73) by $0.01. The company had revenue of $15.30 million for the quarter, compared to analysts’ expectations of $15.17 million. ACADIA Pharmaceuticals had a negative net margin of 948.93% and a negative return on equity of 63.07%. During the same period in the prior year, the company posted ($0.45) EPS. Equities analysts expect that ACADIA Pharmaceuticals will post ($2.83) earnings per share for the current fiscal year.
Several equities research analysts recently issued reports on ACAD shares. Zacks Investment Research upgraded shares of ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, April 14th. Needham & Company LLC reiterated a “buy” rating and issued a $49.00 target price on shares of ACADIA Pharmaceuticals in a research note on Wednesday, April 5th. Rodman & Renshaw reiterated a “buy” rating and issued a $60.00 target price on shares of ACADIA Pharmaceuticals in a research note on Monday, May 22nd. Vetr downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating and set a $41.20 target price for the company. in a research note on Monday, February 27th. Finally, HC Wainwright reiterated a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday, May 10th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and ten have assigned a buy rating to the company’s stock. ACADIA Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $42.88.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by WKRB News and is the sole property of of WKRB News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.wkrb13.com/markets/2229719/acadia-pharmaceuticals-acad-receiving-somewhat-favorable-press-coverage-report-shows.html.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229719/acadia-pharmaceuticals-acad-receiving-somewhat-favorable-press-coverage-report-shows.html
Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.